dabigatran has been researched along with Epistaxis in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agustsson, AS; Bjornsson, ES; Gudmundsdottir, BR; Hreinsson, JP; Ingason, AB; Lund, SH; Onundarson, PT; Palsson, DA; Reynisson, IE; Rumba, E; Tryggvason, G | 1 |
| Buscarini, E; Coote, N; Droege, F; Dupuis-Girod, S; Fialla, AD; Geisthoff, U; Kjeldsen, A; Lenato, GM; Mager, HJ; Manfredi, G; Millar, CM; Pagella, F; Post, MC; Sabbà, C; Shovlin, CL; Suppressa, P; Sure, U; Torring, PM; Ugolini, S | 1 |
| Bari, N; Ho, JPK; Riffat, F | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Bertlich, M; Bootz, F; Eichhorn, KW; Freytag, S; Gräff, I; Horlbeck, F; Jakob, M; Schafigh, D; Send, T | 1 |
| Fleddermann, AM; Hayes, CH; Magalski, A; Main, ML | 1 |
| Finsterer, J; Krutisch, G; Stöllberger, C | 1 |
| Finsterer, J; Krutisch, G; Stöllberger, C; Wolf, HM | 1 |
| Beavers, C; Pahs, L; Schuler, P | 1 |
| Stiefelhagen, P | 1 |
| Musgrave, KM; Powell, J | 1 |
| Franks, AS; Freshour, JE; Hudson, JQ; Stevens, AB | 1 |
1 review(s) available for dabigatran and Epistaxis
| Article | Year |
|---|---|
A systematic review of anti-thrombotic therapy in epistaxis.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Clopidogrel; Dabigatran; Disease Management; Epistaxis; Humans; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Ticlopidine; Tranexamic Acid; Warfarin | 2016 |
11 other study(ies) available for dabigatran and Epistaxis
| Article | Year |
|---|---|
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Epistaxis; Humans; Propensity Score; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Warfarin | 2022 |
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Epistaxis; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Telangiectasia, Hereditary Hemorrhagic; Venous Thromboembolism; Warfarin | 2019 |
Management of epistaxis in patients on novel oral anticoagulation therapy.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index | 2020 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Epistaxis; Female; Follow-Up Studies; Germany; Hospitalization; Humans; Length of Stay; Male; Retrospective Studies; Risk; Rivaroxaban; Treatment Outcome; Warfarin | 2019 |
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus.
Topics: Adult; Aged; Blood Transfusion; Dabigatran; Echocardiography; Epistaxis; Factor Xa Inhibitors; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heart Ventricles; Humans; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Ventricular Dysfunction, Left | 2019 |
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Epistaxis; Female; Humans | 2014 |
Dabigatran-induced lupus temporarily preventing blood group determination.
Topics: Aged, 80 and over; Anemia; Antibodies, Antinuclear; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Group Antigens; Dabigatran; Epistaxis; Female; Humans; Immunoglobulins; Lupus Erythematosus, Systemic | 2014 |
The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban: A Multicenter Evaluation.
Topics: Aged; Aged, 80 and over; Antithrombins; Blood Coagulation Factors; Coagulants; Cohort Studies; Dabigatran; Epistaxis; Erythrocyte Transfusion; Factor VIIa; Factor VIII; Female; Fibrinogen; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Plasma; Platelet Transfusion; Recombinant Proteins; Retrospective Studies; Rivaroxaban | 2015 |
[Nosebleed in new oral anticoagulant treatment - what should be done?].
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Substitution; Epistaxis; Factor Xa Inhibitors; Humans; Long-Term Care; Male; Middle Aged; Rivaroxaban | 2015 |
Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance.
Topics: Aged, 80 and over; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Epistaxis; Female; Humans; Metabolic Clearance Rate | 2012 |